Comparative Pharmacology
Head-to-head clinical analysis: STALEVO 100 versus STALEVO 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STALEVO 100 versus STALEVO 125.
STALEVO 100 vs STALEVO 125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stalevo 100 is a combination of carbidopa, levodopa, and entacapone. Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AAAD), thereby increasing dopamine levels in the brain. Carbidopa inhibits peripheral AAAD, reducing the conversion of levodopa to dopamine outside the brain, which increases the amount of levodopa available for CNS entry and decreases side effects. Entacapone is a reversible inhibitor of catechol-O-methyltransferase (COMT), which reduces the metabolism of levodopa to 3-O-methyldopa, prolonging the half-life and duration of action of levodopa.
Stalevo 125 is a combination of carbidopa, levodopa, and entacapone. Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its availability to the brain. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), primarily in the periphery, which reduces the metabolism of levodopa to 3-O-methyldopa, prolonging the half-life of levodopa.
One tablet (carbidopa 25 mg / levodopa 100 mg / entacapone 200 mg) orally three to four times daily, maximum 8 tablets per day.
One tablet of STALEVO 125 (levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg) orally, one tablet per dose, up to maximum 10 tablets per day. Frequency: typically every 4-6 hours while awake, adjusted based on response.
None Documented
None Documented
Levodopa: 1.5-2 h (peripherally); with carbidopa: prolongs to ~2.5 h. Carbidopa: 2-3 h. Clinical context: requires continuous dopaminergic stimulation to avoid motor fluctuations.
Levodopa: 1-3 hours (short half-life necessitates frequent dosing with carbidopa to reduce peripheral metabolism). Carbidopa: 1-2 hours (not clinically significant alone). Entacapone: 0.4-0.7 hours (short half-life; acts primarily during absorption phase of levodopa).
Renal: ~90% (levodopa metabolites), ~80% (carbidopa unchanged and metabolites); biliary/fecal: minimal
Levodopa: renal excretion of metabolites (dopamine, DOPAC, HVA) accounts for >70% of dose; <1% unchanged. Carbidopa: renal excretion of unchanged drug (~30%) and metabolites (~70%). Entacapone: primarily fecal excretion (~90%) with ~10% renal; entacapone glucuronide and unchanged drug in urine.
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent